CDG & Allies-Professionals and Patient Associations International Network (CDG & Allies-PPAIN), Department of Life Sciences, School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal.
UCIBIO, Department of Life Sciences, NOVA School of Science and Technology, NOVA University of Lisbon, 2819-516 Caparica, Portugal.
Int J Environ Res Public Health. 2022 Jun 2;19(11):6829. doi: 10.3390/ijerph19116829.
Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are almost nonexistent. To better understand the reasons behind this, to analyze ongoing therapy research and development (R&D) for CDG, and to provide future guidance, a community-led mixed methods approach was organized during the 4th World Conference on CDG for Families and Professionals. In the quantitative phase, electronic surveys pointed to the prioritization of six therapeutic R&D tools, namely biobanks, registries, biomarkers, disease models, natural history studies, and clinical trials. Subsequently, in the qualitative phase, the challenges and solutions associated with these research tools were explored through community-driven think tanks. The multiple challenges and solutions identified administrative/regulatory, communication, financial, technical, and biological issues, which are directly related to three fundamental aspects of therapy R&D, namely data, sample, and patient management. An interdependence was traced between the prioritized tools, with diagnosis and therapies acting as bidirectional triggers that fuel these interrelationships. In conclusion, this study's pioneering and adaptable community-led methodology identified several CDG therapy R&D gaps, many common to other rare diseases, without easy solutions. However, the strong proactive attitude towards research, based on inclusive and international partnerships and involving all members of the CDG community, sets the direction for better future therapy R&D.
先天性糖基化障碍(CDG)是一大类罕见的遗传疾病,几乎没有有效的治疗方法。为了更好地了解造成这种情况的原因,分析当前针对 CDG 的治疗研发(R&D)情况,并为未来提供指导,在第四届 CDG 患者及其家属与专业人士世界大会期间,采用了一种由社区主导的混合方法。在定量阶段,电子调查表明有六个治疗 R&D 工具需要优先考虑,即生物库、登记处、生物标志物、疾病模型、自然病史研究和临床试验。随后,在定性阶段,通过社区驱动的智库探讨了这些研究工具所涉及的挑战和解决方案。确定的挑战和解决方案涉及行政/监管、沟通、财务、技术和生物学问题,这些问题直接与治疗 R&D 的三个基本方面有关,即数据、样本和患者管理。优先考虑的工具之间存在相互依存关系,诊断和治疗是促进这些相互关系的双向触发因素。总之,这项开创性和适应性强的由社区主导的研究方法确定了 CDG 治疗研发的几个差距,其中许多与其他罕见疾病共有的问题,没有简单的解决方案。然而,基于包容性和国际化伙伴关系,并让 CDG 社区的所有成员参与的积极主动的研究态度,为未来更好的治疗研发指明了方向。